AR067110A1 - COMBINED PHARMACEUTICAL COMPOSITION - Google Patents
COMBINED PHARMACEUTICAL COMPOSITIONInfo
- Publication number
- AR067110A1 AR067110A1 ARP080102666A ARP080102666A AR067110A1 AR 067110 A1 AR067110 A1 AR 067110A1 AR P080102666 A ARP080102666 A AR P080102666A AR P080102666 A ARP080102666 A AR P080102666A AR 067110 A1 AR067110 A1 AR 067110A1
- Authority
- AR
- Argentina
- Prior art keywords
- cover
- pharmaceutical composition
- polymer
- plasticizer
- antioxidant
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000002998 adhesive polymer Substances 0.000 abstract 2
- 239000003963 antioxidant agent Substances 0.000 abstract 2
- 230000003078 antioxidant effect Effects 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 2
- 239000004005 microsphere Substances 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 239000004014 plasticizer Substances 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 abstract 1
- 229960004005 amlodipine besylate Drugs 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 208000037849 arterial hypertension Diseases 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 229920001688 coating polymer Polymers 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 abstract 1
- 229960002965 pravastatin Drugs 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000011253 protective coating Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Composicion farmacéutica en cápsulas con microesferas recubiertas que comprende la combinacion de besilato de amlodipino y pravastatina sodica y sus sales farmacéuticamente aceptables, adicionalmente vehículos o excipientes farmacéuticamente aceptables; así como a un proceso para la fabricacion de la composicion y al uso de dicha combinacion para la preparacion de un medicamento con actividad terapéutica sinérgica indicado en el tratamiento de padecimientos cardiovasculares del tipo de hipertension arterial y dislipidemia y su comorbilidad. Reivindicacion 3: La composicion .farmacéutica de la reivindicacion 2 caracterizada: porque las microesferas recubiertas comprenden: Nucleos inertes; a) Cubierta uno, que incluye al principio activo uno, al menos un antioxidante, al menos un plastificante, al menos un amortiguador, y al menos un polímero adhesivo ligante aglutinante; b) Cubierta aislante que incluye, al menos un polímero en solucion acuosa; c) Cubierta que incluye al principio activo dos, al menos un antioxidante, al menos un plastificante, al menos un amortiguador, y al menos un polímero adhesivo ligante aglutinante; y d) Cubierta protectora de recubrimiento, que incluye al menos un polímero de recubrimiento y al menos un excipiente.Pharmaceutical composition in capsules with coated microspheres comprising the combination of amlodipine besylate and sodium pravastatin and its pharmaceutically acceptable salts, additionally pharmaceutically acceptable carriers or excipients; as well as a process for the manufacture of the composition and the use of said combination for the preparation of a medication with synergistic therapeutic activity indicated in the treatment of cardiovascular diseases of the type of arterial hypertension and dyslipidemia and their comorbidity. Claim 3: The pharmaceutical composition of claim 2 characterized in that the coated microspheres comprise: inert nuclei; a) Cover one, which includes the active ingredient one, at least one antioxidant, at least one plasticizer, at least one buffer, and at least one binding binder adhesive polymer; b) Insulating cover that includes at least one polymer in aqueous solution; c) Cover which includes at the active principle two, at least one antioxidant, at least one plasticizer, at least one buffer, and at least one binding binder adhesive polymer; and d) Protective coating cover, which includes at least one coating polymer and at least one excipient.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2007008440A MX2007008440A (en) | 2007-07-11 | 2007-07-11 | Combined pharmaceutical composition. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067110A1 true AR067110A1 (en) | 2009-09-30 |
Family
ID=40228222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102666A AR067110A1 (en) | 2007-07-11 | 2008-06-20 | COMBINED PHARMACEUTICAL COMPOSITION |
Country Status (7)
| Country | Link |
|---|---|
| AR (1) | AR067110A1 (en) |
| CL (1) | CL2008001895A1 (en) |
| MX (1) | MX2007008440A (en) |
| PA (1) | PA8785701A1 (en) |
| PE (1) | PE20090439A1 (en) |
| UY (1) | UY31153A1 (en) |
| WO (1) | WO2009007808A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101804055B (en) * | 2010-04-27 | 2012-01-25 | 施慧达药业集团(吉林)有限公司 | Compound medicinal preparation |
| MX351059B (en) * | 2012-08-17 | 2017-09-29 | Laboratorios Senosiain S A De C V Star | Oral pharmaceutical composition in the form of microspheres and preparation method. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ502283A (en) * | 1997-08-29 | 2002-05-31 | Pfizer Prod Inc | Cardiovascular therapy comprising amlodipine and a statin compound in amounts that are synergistically effective |
| EP1314425A4 (en) * | 2000-08-30 | 2004-06-02 | Sankyo Co | Medicinal compositions for preventing or treating heart failure |
-
2007
- 2007-07-11 MX MX2007008440A patent/MX2007008440A/en active IP Right Grant
-
2008
- 2008-06-13 UY UY31153A patent/UY31153A1/en not_active Application Discontinuation
- 2008-06-14 WO PCT/IB2008/001538 patent/WO2009007808A1/en not_active Ceased
- 2008-06-20 AR ARP080102666A patent/AR067110A1/en unknown
- 2008-06-25 PA PA20088785701A patent/PA8785701A1/en unknown
- 2008-06-26 CL CL200801895A patent/CL2008001895A1/en unknown
- 2008-07-09 PE PE2008001152A patent/PE20090439A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CL2008001895A1 (en) | 2008-08-22 |
| MX2007008440A (en) | 2009-02-18 |
| PE20090439A1 (en) | 2009-05-24 |
| WO2009007808A1 (en) | 2009-01-15 |
| WO2009007808A4 (en) | 2009-03-05 |
| UY31153A1 (en) | 2009-03-02 |
| PA8785701A1 (en) | 2009-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200222A1 (en) | Crystalline forms of the proton tyrosine kinase inhibitor | |
| EP4342540A3 (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| MX2019010354A (en) | Heteroaryl[4,3-c]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof. | |
| ECSP12011838A (en) | CHROMENONE DERIVATIVES WITH ANTI-TUMORAL ACTIVITY | |
| CL2011003266A1 (en) | Compounds derived from imidazolidin-2-one, with inhibitory activity of 17alpha-hydroxylase / lyase-c17,20; pharmaceutical composition comprising them; and use in the treatment of inflammation or cancer, among others. | |
| DOP2010000011A (en) | DERIVATIVES OF PIRIMIDINE TRISUSTITUIDA FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
| DK2324008T3 (en) | Diarylpyrazole as protein kinase inhibitors | |
| BR112018015273A2 (en) | benzimidazole derivatives as ror-gamma modulators | |
| ECSP109935A (en) | PYRIMIDINE MORFOLINE DERIVATIVES USED IN DISEASES RELATED TO MTOR QUINASA AND / OR PI3K | |
| BR112015018087A8 (en) | compound, pharmaceutical composition and use | |
| CR20170563A (en) | BENZOXACEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE. | |
| GT200600096A (en) | PHARMACEUTICAL COMPOSITION FOR CANCER TREATMENT | |
| ECSP109934A (en) | COMPOUND - 946 | |
| UY33183A (en) | INHIBITING COMPOUNDS OF VIRUS FLAVIVIRIDAE, PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT | |
| CL2013001339A1 (en) | Condensed heterocyclic derivative compounds, with antiviral activity; pharmaceutical composition that includes them; and its use for the prevention or treatment of HIV infection. | |
| BR112015030315A2 (en) | 4-alkynylimidazole derivative and medicament comprising the same as active ingredient | |
| CL2015002608A1 (en) | Amino-pyrazole compound and related medicinal uses. | |
| BR112014010563A2 (en) | aminopyrimidine kinase inhibitors | |
| CL2011000798A1 (en) | Use of dabigatran etexilate or a salt thereof to prepare a useful medication for the prevention of stroke in patients suffering from atrial fibrillation. | |
| ECSP14013275A (en) | DERIVATIVES OF ESTRA-1,3,5 (10), 16-TETRAEN-3-CARBOXAMIDE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES | |
| CR20180184A (en) | HETEROARILO COMPOUNDS AND ITS USE AS THERAPEUTIC DRUGS | |
| CL2007000781A1 (en) | NANOPARTICLES THAT INCLUDE A THYROSINE KINASE INHIBITOR RECEIVING THE GROWTH FACTOR DERIVED FROM PLATES; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF VASCULAR DISEASES, SUCH AS RESTENOSIS | |
| CR20110704A (en) | COMPOSITIONS OF FIXED DOSAGE SOLID PHARMACEUTICALS THAT INCLUDE IRBESARTAN AND AMYLODIPINE, ITS PREPARATION AND THERAPEUTIC APPLICATION | |
| BR112015023356A2 (en) | pyrrol [2,3-b] pyridine cdk9 kinase inhibitors | |
| EP4361174A4 (en) | ACYLATED INSULIN-CONTAINING PHARMACEUTICAL COMPOSITION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |